Print
Email
Print Edition StoriesWednesday, December 2, 2009
Taris successfully completes Phase 1 drug delivery device study
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: RI plans launch of cord blood center
Taris Biomedical has announced a succesful completion of its Phase 1 clinical study of a device intended for sustained release of a drug into the bladder. The study evaluated safety, tolerance and retention of the system.
The intravesical drug-device convergence system is intended for use with lidocaine to ease bladder disease symptoms. The company said in a press release that it expects to bring its LiRIS (Lidocaine Releasing Intravesical System) to mid-stage clinical studies in 2010.
Intravesical systems are already used for drug delivery, but often require multiple dosages. Taris’ technology, a platform to allow drugs to slowly seep out of semi-permeable tube devices, is based on research performed by MIT scientists Michael Cima and Robert Langer. The drug device can be used for a number of diseases affecting organs difficult to target.
More about Taris
Lexington-based Taris Biomedical announced in June that it received a $15 million Series A round of venture financing to fund the early stage trials of the device for bladder disease.
The company operated in stealth mode for about 10 months before emerging in June.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
